{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:13:17Z","timestamp":1788624797742,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dysphagia is a common and clinically significant complication in idiopathic inflammatory myopathies, contributing to aspiration pneumonia, malnutrition, and reduced quality of life. However, its prognostic significance in terms of survival and swallowing outcomes remains unclear. A narrative review was conducted using PubMed to identify relevant studies published between January 2000 and April 2026. Dysphagia in idiopathic inflammatory myopathies is associated with increased mortality, primarily due to aspiration-related complications and underlying disease severity. Emerging evidence indicates that this association may be modified by the presence of malignancy, particularly in dermatomyositis. Swallowing outcomes are heterogeneous: some patients show improvement with immunosuppressive therapy or intravenous immunoglobulin, whereas others experience persistent or progressive dysfunction, especially those with inclusion body myositis. Key prognostic factors include age, disease subtype, autoantibody status, and baseline severity of dysphagia. Dysphagia in idiopathic inflammatory myopathies should be recognized as a clinically important manifestation associated with both survival and functional outcomes. Early identification and appropriate management are essential to improve patient prognosis. Further prospective studies are needed to establish standardized assessment and risk stratification strategies.<\/jats:p>","DOI":"10.1093\/mr\/roag071","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:39:08Z","timestamp":1787053148000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of dysphagia in idiopathic inflammatory myopathies: A narrative review of survival and functional outcomes"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4149","authenticated-orcid":false,"given":"Shin-ichiro","family":"Ohmura","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026090512064484000_ref1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2026090512064484000_ref2","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026090512064484000_ref3","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/jcm9072150","article-title":"The impact of dysphagia in myositis: a systematic review and meta-analysis","volume":"9","author":"Labeit","year":"2020","journal-title":"J Clin Med"},{"key":"2026090512064484000_ref4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-020-00950-3","article-title":"Impact and management of dysphagia in inflammatory myopathies","volume":"22","author":"Zeng","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"2026090512064484000_ref5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4065\/82.4.441","article-title":"Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients","volume":"82","author":"Oh","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"2026090512064484000_ref6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/gut.52.4.471","article-title":"Biomechanics, diagnosis, and treatment outcome in inflammatory myopathy presenting as oropharyngeal dysphagia","volume":"52","author":"Williams","year":"2003","journal-title":"Gut"},{"key":"2026090512064484000_ref7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/PHM.0b013e31818a50e2","article-title":"Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome","volume":"87","author":"Oh","year":"2008","journal-title":"Am J Phys Med Rehabil"},{"key":"2026090512064484000_ref8","first-page":"838","article-title":"Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients","volume":"30","author":"Dobloug","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026090512064484000_ref9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/1756-185X.14365","article-title":"Impact of dysphagia and its severity on long-term survival and swallowing function outcomes in patients with idiopathic inflammatory myopathies other than inclusion body myositis","volume":"25","author":"Ohmura","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"2026090512064484000_ref10","first-page":"e71821","article-title":"Long-term dysphagia severity in patients with idiopathic inflammatory myopathy: a single-center retrospective study","volume":"16","author":"Ohmura","year":"2024","journal-title":"Cureus"},{"key":"2026090512064484000_ref11","doi-asserted-by":"crossref","first-page":"152408","DOI":"10.1016\/j.semarthrit.2024.152408","article-title":"Effect modification of cancer on the association between dysphagia and mortality in early idiopathic inflammatory myopathies","volume":"65","author":"Leclair","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026090512064484000_ref12","first-page":"165","article-title":"Prognosis of dysphagia in dermatomyositis","volume":"37","author":"Ogawa-Momohara","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2026090512064484000_ref13","doi-asserted-by":"crossref","DOI":"10.1007\/s00455-026-10932-9","article-title":"Association between oropharyngeal dysphagia and subgroups of patients with idiopathic inflammatory myopathy: a cross-sectional study","volume":"41","author":"Segura-Hernandez","year":"2026","journal-title":"Dysphagia"},{"key":"2026090512064484000_ref14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-025-03662-0","article-title":"Revisiting the link between oropharyngeal dysphagia and cancer in autoimmune myositis: a descriptive study","volume":"27","author":"Shen","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"2026090512064484000_ref15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/BOR.0000000000001060","article-title":"Inclusion body myositis: an update","volume":"37","author":"Anderson","year":"2025","journal-title":"Curr Opin Rheumatol"},{"key":"2026090512064484000_ref16","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026090512064484000_ref17","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/ar4332","article-title":"Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome","volume":"15","author":"Marie","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2026090512064484000_ref18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1080\/03009742.2021.1941243","article-title":"Re-evaluation of the prognostic significance of oropharyngeal dysphagia in idiopathic inflammatory myopathies","volume":"51","author":"Kim","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"2026090512064484000_ref19","doi-asserted-by":"crossref","first-page":"e0154746","DOI":"10.1371\/journal.pone.0154746","article-title":"Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies","volume":"11","author":"Mugii","year":"2016","journal-title":"PLoS One"},{"key":"2026090512064484000_ref20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"2026090512064484000_ref21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13023-016-0524-x","article-title":"Multicenter questionnaire survey for sporadic inclusion body myositis in Japan","volume":"11","author":"Suzuki","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"2026090512064484000_ref22","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1474-4422(07)70171-0","article-title":"Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches","volume":"6","author":"Needham","year":"2007","journal-title":"Lancet Neurol"},{"key":"2026090512064484000_ref23","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/brain\/awr217","article-title":"A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities","volume":"134","author":"Cox","year":"2011","journal-title":"Brain"},{"key":"2026090512064484000_ref24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/IJGM.S198031","article-title":"Dysphagia in patients with sporadic inclusion body myositis: management challenges","volume":"12","author":"Mohannak","year":"2019","journal-title":"Int J Gen Med"},{"key":"2026090512064484000_ref25","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026090512064484000_ref26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2026090512064484000_ref27","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/rheumatology\/keaa443","article-title":"Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis","volume":"60","author":"Giannini","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026090512064484000_ref28","first-page":"A02250076","article-title":"Intravenous immunoglobulin is an effective steroid-sparing drug in inflammatory myositis","volume":"72","author":"Nannarup","year":"2025","journal-title":"Dan Med J"},{"key":"2026090512064484000_ref29","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/mus.27225","article-title":"Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy","volume":"63","author":"Labeit","year":"2021","journal-title":"Muscle Nerve"},{"key":"2026090512064484000_ref30","first-page":"8837463","article-title":"A case report of anti-TIF1-\u03b3 antibody-positive dermatomyositis concomitant with small cell neuroendocrine carcinoma of the urinary bladder","volume":"2023","author":"Hounoki","year":"2023","journal-title":"Case Rep Rheumatol"},{"key":"2026090512064484000_ref31","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40744-025-00775-5","article-title":"Efficacy of intravenous immunoglobulin for systemic manifestations of dermatomyositis beyond muscular and cutaneous: sub-analysis of the ProDERM Study","volume":"12","author":"Aggarwal","year":"2025","journal-title":"Rheumatol Ther"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag071\/70709086\/roag071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag071\/70709086\/roag071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:06:58Z","timestamp":1788624418000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/advance-article\/doi\/10.1093\/mr\/roag071\/8766053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1093\/mr\/roag071","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"roag071"}}